{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T17:12:07Z","timestamp":1785604327042,"version":"3.56.0"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T00:00:00Z","timestamp":1262649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:italic>Objective:<\/jats:italic>\u2002The efficacy of pirarubicin (THP)\u2010COP was previously compared with cyclophophamide + doxorubicin + vincristine + prednisolone (CHOP) in elderly patients with lymphoma. The subset analysis showed that T\u2010cell lymphoma had a significantly better response with THP\u2010COP, whereas no such difference was observed in B\u2010cell lymphoma. The aim of this study is to confirm the efficacy of THP\u2010COP in the treatment of T\u2010cell lymphoma. <jats:italic>Methods:<\/jats:italic>\u2002We underwent a multicenter phase II study of THP\u2010COP as a first\u2010line treatment for T\u2010cell lymphoma. The overall response rate, survival period, and toxicity were analyzed. <jats:italic>Results:<\/jats:italic>\u2002Fifty\u2010three patients were enrolled in this study. Seventeen patients had peripheral T\u2010cell lymphoma (PTCL), including nine of PTCL not otherwise specified (PTCL\u2010NOS) and eight of angioimmunoblastic T\u2010cell lymphoma (AITL). Thirty\u2010six patients had adult T\u2010cell leukemia\/lymphoma (ATLL), including 20 of acute type and 16 of lymphoma type. A treatment response was obtained in 35 (66%) patients, including 17 (32%) complete responses. Median overall survival (OS) and progression\u2010free survival (PFS) times were 14.3\u2003months and 5.2\u2003months, respectively. Patients with ATLL showed a tendency to obtain low response rate (61% vs. 77%, <jats:italic>P<\/jats:italic>\u2003=\u20030.27) and had a significantly inferior OS (13.3 vs. 28.6\u2003months, <jats:italic>P<\/jats:italic>\u2003=\u20030.04) and PFS (4.6 vs. 8.1\u2003months, <jats:italic>P<\/jats:italic>\u2003=\u20030.01) in comparison with PTCL. Grade 3 to 4 neutropenia, anemia, and thrombocytopenia occurred in 72%, 34%, and 58% of the patients, respectively. Febrile neutropenia was observed in 51% and grade 3 non\u2010hematological toxicities in 2\u20139% of the patients. <jats:italic>Conclusion:<\/jats:italic>\u2002The efficacy of THP\u2010COP is equivalent to that of CHOP for the first\u2010line therapy in T\u2010cell lymphoma.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01411.x","type":"journal-article","created":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T15:02:27Z","timestamp":1262703747000},"page":"391-397","source":"Crossref","is-referenced-by-count":20,"title":["THP\u2010COP regimen for the treatment of peripheral T\u2010cell lymphoma and adult T\u2010cell leukemia\/lymphoma: a multicenter phase II study"],"prefix":"10.1111","volume":"84","author":[{"given":"Yasushi","family":"Takamatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Suzushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Kyushu Hematology Organization for Treatment Study Group (K\u2010HOT)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,13]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265532487"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1827.2002.01308.x"},{"key":"e_1_2_6_4_2","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht C","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01137.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.697.11.2","article-title":"Phase I\/II study of the rituximab\u2010EPOCT regimen in combination with granulocyte colony\u2010stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B\u2010type natriuretic peptide and troponin T levels","volume":"11","author":"Niitsu N","year":"2005","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_8_2","first-page":"465","article-title":"Effect of pirarubicin for elderly patients with malignant lymphoma","volume":"17","author":"Aoki S","year":"1998","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.03147"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109057991"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.2428"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn696"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.9958"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105759"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2095"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.815"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01411.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01411.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T15:36:24Z","timestamp":1698766584000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01411.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,13]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01411.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01411.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,13]]}}}